ReviewJournal of fungi (Basel, Switzerland)2025
Mycobiota and Antifungal Antibodies as Emerging Targets for the Diagnosis and Prognosis of Human Diseases.
Review in Journal of fungi (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The human body is colonized by diverse microorganisms, with bacteria being the most extensively studied. However, fungi, collectively known as "the mycobiota," are increasingly recognized as integral components of the microbiota, inhabiting nearly all mucosal surfaces. Commensal fungi influence host immunity similarly to bacteria and contribute to other essential functions, including metabolism. This emerging understanding positions fungi as potential biomarkers for the diagnosis and prognosis of various diseases. In this review, we explore the dual roles of fungi as both commensals and pathogens, and the potential of antifungal antibodies to serve as diagnostic and prognostic tools, especially in chronic immune-inflammatory non-communicable diseases, including inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and neurodegenerative disorders. Finally, we address current challenges and outline future perspectives for leveraging fungal biomarkers in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.